Fig. 1: TCP1 is highly expressed in malignant tumours and predicts a poor prognosis.

a The levels of TCP1 expression were greater in most solid tumour tissues than in normal groups in TCGA database. ACC adrenocortical cancer, BLCA bladder cancer, BRCA breast cancer, CESC cervical cancer, CHOL bile duct cancer, COAD colon adenocarcinoma, DLBC large B-cell lymphoma, ESCA esophageal cancer, GBM glioblastoma, HNSC head and neck cancer; KICH kidney chromophobe, KIRC kidney chromophobe, KIRP kidney chromophobe, LAML acute myeloid leukaemia, LGG acute myeloid leukaemia, LIHC liver cancer, LUAD lung adenocarcinoma, LUSC lung squamous cell carcinoma, OV ovarian cancer, PAAD pancreatic cancer, PCPG pheochromocytoma & paraganglioma, PRAD prostate cancer, READ prostate cancer, SARC sarcoma, SKCM melanoma, STAD stomach cancer, TGCT testicular cancer, THCA thyroid cancer, THYM thymoma, UCEC endometrioid cancer, UCS uterine carcinosarcoma. b Kaplan–Meier survival analysis revealed that high TCP1 expression was correlated with significantly shorter overall survival (OS) in patients with breast cancer and lung cancer. c IHC was carried out, and the relative TCP1 staining intensity was scored to analyse TCP1 expression levels in adjacent and malignant tumours. d, f, h Fluorescence imaging and IHC were used to determine the relationship between TCP1 expression and the degree of differentiation in liver and pancreatic cancers. Representative images and the relative scores of TCP1 are shown for liver cancer d and pancreatic cancer f, h tissues. Scale bar, 200 μm. e, g Pearson correlation analysis revealed that the TCP1 level was negatively correlated with recurrence time in patients with HCC (e) and PDAC (g). i, j Relationships between TCP1 expression and overall survival (OS) (i) and disease-free survival (DFS) (j) rates in pancreatic cancer patients. The data are shown as the means ± SDs from three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, ns, no significance, between the indicated groups.